Cargando…

SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC

SLC1A4, a Na-dependent neutral amino acid transporter, was considered to participate in the various pathobiological process, including tumorigenesis. However, the correlation between SLC1A4 and Hepatocellular Carcinoma (HCC) remains unclear. In our study, integrative bioinformatics and functional pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Xiaozhen, Chen, Ruochan, Cai, Shenglan, Lu, Shanshan, Zhang, Yiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991385/
https://www.ncbi.nlm.nih.gov/pubmed/33777811
http://dx.doi.org/10.3389/fonc.2021.650355
_version_ 1783669196659359744
author Peng, Xiaozhen
Chen, Ruochan
Cai, Shenglan
Lu, Shanshan
Zhang, Yiya
author_facet Peng, Xiaozhen
Chen, Ruochan
Cai, Shenglan
Lu, Shanshan
Zhang, Yiya
author_sort Peng, Xiaozhen
collection PubMed
description SLC1A4, a Na-dependent neutral amino acid transporter, was considered to participate in the various pathobiological process, including tumorigenesis. However, the correlation between SLC1A4 and Hepatocellular Carcinoma (HCC) remains unclear. In our study, integrative bioinformatics and functional profiling were performed to reveal the prognosis and potential function of SLC1A4 in HCC. The results showed that the mRNA and protein levels of SLC1A4 were elevated in HCC, and it was a powerful independent prognostic marker for overall survival (OS). The co-expressed genes analysis and GSEA analysis showed that SLC1A4 was related to cell cycle, metabolism, cancer-related pathway. Furthermore, the functional analysis revealed that silenced SLC1A4 inhibited cell proliferation, migration, cell cycle, and promoted cell apoptosis in HCC. Next, immune analysis showed that SLC1A4 expression was positively associated with immune infiltration and immune-related chemokine expression in HCC. Silenced SLC1A4 evidently reduced these chemokines expression in HCC cells. Finally, drug sensitivity analysis revealed potential five sensitivity drugs for HCC patients with high-expressed SLC1A4. In conclusion, our results suggested that SLCIA4 could be a novel predictor prognosis and immunotherapeutic targets of HCC, and the sensitivity drugs may be effective therapeutic strategy for HCC patients with high-expressed SLC1A4.
format Online
Article
Text
id pubmed-7991385
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79913852021-03-26 SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC Peng, Xiaozhen Chen, Ruochan Cai, Shenglan Lu, Shanshan Zhang, Yiya Front Oncol Oncology SLC1A4, a Na-dependent neutral amino acid transporter, was considered to participate in the various pathobiological process, including tumorigenesis. However, the correlation between SLC1A4 and Hepatocellular Carcinoma (HCC) remains unclear. In our study, integrative bioinformatics and functional profiling were performed to reveal the prognosis and potential function of SLC1A4 in HCC. The results showed that the mRNA and protein levels of SLC1A4 were elevated in HCC, and it was a powerful independent prognostic marker for overall survival (OS). The co-expressed genes analysis and GSEA analysis showed that SLC1A4 was related to cell cycle, metabolism, cancer-related pathway. Furthermore, the functional analysis revealed that silenced SLC1A4 inhibited cell proliferation, migration, cell cycle, and promoted cell apoptosis in HCC. Next, immune analysis showed that SLC1A4 expression was positively associated with immune infiltration and immune-related chemokine expression in HCC. Silenced SLC1A4 evidently reduced these chemokines expression in HCC cells. Finally, drug sensitivity analysis revealed potential five sensitivity drugs for HCC patients with high-expressed SLC1A4. In conclusion, our results suggested that SLCIA4 could be a novel predictor prognosis and immunotherapeutic targets of HCC, and the sensitivity drugs may be effective therapeutic strategy for HCC patients with high-expressed SLC1A4. Frontiers Media S.A. 2021-03-11 /pmc/articles/PMC7991385/ /pubmed/33777811 http://dx.doi.org/10.3389/fonc.2021.650355 Text en Copyright © 2021 Peng, Chen, Cai, Lu and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Peng, Xiaozhen
Chen, Ruochan
Cai, Shenglan
Lu, Shanshan
Zhang, Yiya
SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC
title SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC
title_full SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC
title_fullStr SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC
title_full_unstemmed SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC
title_short SLC1A4: A Powerful Prognostic Marker and Promising Therapeutic Target for HCC
title_sort slc1a4: a powerful prognostic marker and promising therapeutic target for hcc
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991385/
https://www.ncbi.nlm.nih.gov/pubmed/33777811
http://dx.doi.org/10.3389/fonc.2021.650355
work_keys_str_mv AT pengxiaozhen slc1a4apowerfulprognosticmarkerandpromisingtherapeutictargetforhcc
AT chenruochan slc1a4apowerfulprognosticmarkerandpromisingtherapeutictargetforhcc
AT caishenglan slc1a4apowerfulprognosticmarkerandpromisingtherapeutictargetforhcc
AT lushanshan slc1a4apowerfulprognosticmarkerandpromisingtherapeutictargetforhcc
AT zhangyiya slc1a4apowerfulprognosticmarkerandpromisingtherapeutictargetforhcc